Home > Insider Trading > Filing (0001209191-21-022705)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1783183	Phathom Pharmaceuticals Inc.	PHAT	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1690298	Terrie Curran	C/O Phathom Pharmaceuticals, Inc. 100 Campus Drive, Suite 102 Florham Park NJ 07932	President And Chief Executive	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-03-22	11,513	$6.95	11,513	No	4	M	Direct
Common Stock	Disposition	2021-03-22	10,373	$43.24	1,140	No	4	S	Direct
Common Stock	Disposition	2021-03-22	1,140	$44.08	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2021-03-22	11,513	$0.00	11,513	$6.95

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
855,687		2029-08-28	No	4	M	Direct

Footnotes

Represents shares of common stock received upon exercising a stock option.
All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.82 to $43.81. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.82 to $44.71. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The stock option was granted on August 29, 2019 and vested with respect to 25% of the shares of common stock on August 29, 2020, and thereafter vests in equal monthly installments over the following three years.